Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,521 to 2,540 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Donning Non-Sterile Gloves Without Hand Hygiene vs Hand Hygiene Before Donning Non-Sterile Gloves: Proportion of Healthcare Workers Who Perform Hand Hygiene on Entry Into Non-contact Precaution Room | 1,111 of 1,688 951 of 1,315 | -6.5 points -9.8 to -3.2 | 3,003 | NCT03119389 Direct Gloving Strategy: A Cluster-randomized Trial |
| Fondaparinux 2.5 mg vs Placebo: Number of Participants With at Least One Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 77 | 18 of 1,502 94 of 1,500 | -5.1 points -6.5 to -3.8 | 3,002 | NCT00443053 Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis) |
| Fondaparinux 2.5 mg vs Placebo: Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47 | 13 of 1,502 88 of 1,500 | -5.0 points -6.4 to -3.8 | 3,002 | NCT00443053 Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis) |
| RPT Plus INH Regimen (Arm A) vs INH Regimen (Arm B): deaths from any cause | 21 of 1,496 27 of 1,504 | -0.4 points -1.3 to 0.5 | 3,000 | NCT01404312 Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB) |
| RPT Plus INH Regimen (Arm A) vs INH Regimen (Arm B): serious adverse events | 40 of 1,496 68 of 1,504 | -1.8 points -3.2 to -0.5 | 3,000 | NCT01404312 Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB) |
| Endotracheal Intubation vs Laryngeal Tube (King): Return of Spontaneous Circulation (ROSC) | 361 of 1,495 420 of 1,505 | -3.8 points -6.9 to -0.6 | 3,000 | NCT02419573 Pragmatic Airway Resuscitation Trial |
| Endotracheal Intubation vs Laryngeal Tube (King): Number of Patients Alive at 72 Hours After Episode. | 230 of 1,495 275 of 1,505 | -2.9 points -5.6 to -0.2 | 3,000 | NCT02419573 Pragmatic Airway Resuscitation Trial |
| Endotracheal Intubation vs Laryngeal Tube (King): deaths from any cause | 1,265 of 1,495 1,230 of 1,505 | 2.9 points 0.2 to 5.6 | 3,000 | NCT02419573 Pragmatic Airway Resuscitation Trial |
| TAVR With Sentinel vs TAVR Without Sentinel: deaths from any cause | 11 of 1,501 7 of 1,499 | 0.3 points -0.3 to 0.9 | 3,000 | NCT04149535 PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement |
| TAVR With Sentinel vs TAVR Without Sentinel: The Rate of Stroke Through 72 Hours Post TAVR Procedure or Discharge (Whichever Comes First) | 34 of 1,501 43 of 1,499 | -0.6 points -1.8 to 0.5 | 3,000 | NCT04149535 PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement |
| TAVR With Sentinel vs TAVR Without Sentinel: serious adverse events | 285 of 1,501 315 of 1,499 | -2.0 points -4.9 to 0.8 | 3,000 | NCT04149535 PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement |
| Endotracheal Intubation vs Laryngeal Tube (King): Number of Patients Alive at Hospital Discharge | 121 of 1,495 163 of 1,504 | -2.7 points -4.8 to -0.6 | 2,999 | NCT02419573 Pragmatic Airway Resuscitation Trial |
| qHPV vs Placebo: serious adverse events | 38 of 1,499 43 of 1,498 | -0.3 points -1.5 to 0.8 | 2,997 | NCT00834106 Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) |
| Endotracheal Intubation vs Laryngeal Tube (King): Number of Patients With Favorable Neurologic Status on Hospital Discharge | 75 of 1,495 107 of 1,500 | -2.1 points -3.8 to -0.4 | 2,995 | NCT02419573 Pragmatic Airway Resuscitation Trial |
| MEDI8897 vs Placebo: deaths from any cause | 5 of 1,997 0 of 997 | 0.3 points -0.2 to 0.6 | 2,994 | NCT03979313 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) |
| MEDI8897 vs Placebo: serious adverse events | 149 of 1,997 83 of 997 | -0.9 points -3.0 to 1.1 | 2,994 | NCT03979313 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) |
| Standard RRT Initiation vs Accelerated RRT Initiation: serious adverse events | 8 of 1,489 15 of 1,503 | -0.5 points -1.2 to 0.2 | 2,992 | NCT02568722 Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial) |
| Arm G - Metformin vs Arm G - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death | 54 of 1,443 49 of 1,548 | 0.6 points -0.7 to 1.9 | 2,991 | NCT06042855 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) |
| Arm G - Metformin vs Arm G - Placebo: Number of Participants With Hospitalization or Death | 4 of 1,443 3 of 1,548 | 0.1 points -0.3 to 0.5 | 2,991 | NCT06042855 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) |
| Arm G - Metformin vs Arm G - Placebo: serious adverse events | 7 of 1,443 3 of 1,548 | 0.3 points -0.2 to 0.8 | 2,991 | NCT06042855 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=127"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=127
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03119389-9bb16884",
"title": "Donning Non-Sterile Gloves Without Hand Hygiene vs Hand Hygiene Before Donning Non-Sterile Gloves: Proportion of Healthcare Workers Who Perform Hand Hygiene on Entry Into Non-contact Precaution Room",
"summary": "1111 of 1688 against 951 of 1315; risk difference -6.5 points, 95% interval -9.8 to -3.2; NCT03119389, Direct Gloving Strategy: A Cluster-randomized Trial",
"record": "/library/comparisons/NCT03119389-9bb16884",
"nct_id": "NCT03119389",
"kind": "outcome",
"participants": 3003,
"risk_difference": {
"value": -0.06501856089957292,
"lower": -0.09787972235522363,
"upper": -0.03169892261423946
},
"group_1": "1,111 of 1,688",
"group_2": "951 of 1,315",
"difference": "-6.5 points",
"interval": "-9.8 to -3.2",
"trial_title": "Direct Gloving Strategy: A Cluster-randomized Trial"
},
{
"id": "NCT00443053-8a08e305",
"title": "Fondaparinux 2.5 mg vs Placebo: Number of Participants With at Least One Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 77",
"summary": "18 of 1502 against 94 of 1500; risk difference -5.1 points, 95% interval -6.5 to -3.8; NCT00443053, Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)",
"record": "/library/comparisons/NCT00443053-8a08e305",
"nct_id": "NCT00443053",
"kind": "outcome",
"participants": 3002,
"risk_difference": {
"value": -0.0506826453617399,
"lower": -0.06479994659162429,
"upper": -0.0375526696314879
},
"group_1": "18 of 1,502",
"group_2": "94 of 1,500",
"difference": "-5.1 points",
"interval": "-6.5 to -3.8",
"trial_title": "Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=128",
"request_id": "ebPklYj7MlPfh4Re"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant